Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to $49,000.

  • Foghorn Therapeutics' Cash from Financing Activities fell 95.34% to $49,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $446,000, marking a year-over-year decrease of 99.58%. This contributed to the annual value of $105.4 million for FY2024, which is 5829.58% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Cash from Financing Activities stood at $49,000 for Q3 2025, which was down 80.71% from $254,000 recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Cash from Financing Activities peaked at $103.2 million during Q2 2024, and registered a low of $4,000 during Q4 2024.
  • In the last 3 years, Foghorn Therapeutics' Cash from Financing Activities had a median value of $186,000 in 2023 and averaged $9.8 million.
  • Per our database at Business Quant, Foghorn Therapeutics' Cash from Financing Activities plummeted by 99.93% in 2022 and then soared by 100,100.00% in 2024.
  • Foghorn Therapeutics' Cash from Financing Activities (Quarterly) stood at $21.7 million in 2021, then plummeted by 99.93% to $16,000 in 2022, then surged by 1,062.50% to $186,000 in 2023, then slumped by 97.85% to $4,000 in 2024, then tumbled by 95.34% to $49,000 in 2025.
  • Its Cash from Financing Activities stands at $49,000 for Q3 2025, versus $254,000 for Q2 2025 and $139,000 for Q1 2025.